Corbus Pharmaceuticals Holdings, Inc. Stock
Equities
CRBP
US21833P3010
Biotechnology & Medical Research
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
35.64 USD | +4.06% | -5.46% | +490.07% |
Sales 2024 * | - | Sales 2025 * | - | Capitalization | 374M 512M |
---|---|---|---|---|---|
Net income 2024 * | -53M -72.48M | Net income 2025 * | -65M -88.89M | EV / Sales 2024 * | - |
Net cash position 2024 * | - 0 | Net cash position 2025 * | - 0 | EV / Sales 2025 * | - |
P/E ratio 2024 * |
-6.85
x | P/E ratio 2025 * |
-6.96
x | Employees | 19 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 99.31% |
Latest transcript on Corbus Pharmaceuticals Holdings, Inc.
1 day | +4.06% | ||
1 week | -5.46% | ||
Current month | -9.17% | ||
1 month | -9.17% | ||
3 months | +91.41% | ||
6 months | +584.07% | ||
Current year | +490.07% |
Managers | Title | Age | Since |
---|---|---|---|
Yuval Cohen
CEO | Chief Executive Officer | 49 | 13-06-30 |
Sean Moran
DFI | Director of Finance/CFO | 66 | 14-04-10 |
Chief Tech/Sci/R&D Officer | 50 | 02-27 |
Members of the board | Title | Age | Since |
---|---|---|---|
Alan Holmer
CHM | Chairman | 74 | 13-12-31 |
Avery Catlin
BRD | Director/Board Member | 75 | 14-07-31 |
Yuval Cohen
CEO | Chief Executive Officer | 49 | 13-06-30 |
Date | Price | Change | Volume |
---|---|---|---|
24-04-29 | 35.64 | +4.06% | 92,795 |
24-04-26 | 34.25 | +2.24% | 96,876 |
24-04-25 | 33.5 | -5.74% | 142,333 |
24-04-24 | 35.54 | -5.83% | 221,002 |
24-04-23 | 37.74 | +0.11% | 500,521 |
Delayed Quote Nasdaq, April 29, 2024 at 04:00 pm
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+490.07% | 360M | |
-2.63% | 103B | |
+1.62% | 95.28B | |
+1.46% | 22.15B | |
-16.67% | 21.02B | |
-8.58% | 18.15B | |
-38.74% | 16.73B | |
-13.21% | 16.05B | |
+5.41% | 13.68B | |
+33.57% | 12.17B |
- Stock Market
- Equities
- CRBP Stock